NEW ORLEANS, Sept. 18, 2026 /PRNewswire/ — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX), if they purchased or otherwise acquired the Company’s common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
Get Help
Beta Bionics investors should visit us at https://claimsfiler.com/cases/nasdaq-bbnx/ or call toll-free (833) 538-3604. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Beta Bionics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) the Company’s sole commercialized device, the iLet Bionic Pancreas insulin pump (“iLet”), employed an aggressive automated dosing algorithm that malfunctioned and delivered dangerously high levels of insulin, causing hypoglycemic events, including hundreds of life-threatening events requiring medical intervention and hospitalization; (ii) the Company had received thousands of related customer complaints that it failed to investigate or timely report to the U.S. Food and Drug Administration (“FDA”); (iii) the FDA Form 483 issued to the Company in June 2025 identified more than 18,000 unreported complaints and was not, as Defendants represented, limited to a minor difference in interpretation of which complaints were reportable; (iv) the Company had failed to implement meaningful corrective actions in response to the Form 483, resulting in an FDA warning letter concerning the Company’s quality management system, medical device reporting, and corrections and removals; and (v) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
The case is Holtzman v. Beta Bionics, Inc., et al., No. 26-cv-09999.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
(833) 538-3604
View original content to download multimedia:https://www.prnewswire.com/news-releases/beta-bionics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-beta-bionics-inc—bbnx-302883658.html
SOURCE ClaimsFiler
